{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:30:23Z","timestamp":1785522623089,"version":"3.56.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy &amp; Behavior"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.yebeh.2021.107958","type":"journal-article","created":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T11:53:40Z","timestamp":1619006020000},"page":"107958","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Evaluation of the Aberrant Behavior Checklist for Developmental and Epileptic Encephalopathies"],"prefix":"10.1016","volume":"119","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8147-1899","authenticated-orcid":false,"given":"Aaron J.","family":"Kaat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3560-7323","authenticated-orcid":false,"given":"Frank","family":"Zelko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greta","family":"Wilkening","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne T.","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2021.107958_b0005","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41582-018-0099-3","article-title":"From molecules to medicines: the dawn of targeted therapies for genetic epilepsies","volume":"14","author":"Demarest","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.yebeh.2021.107958_b0010","doi-asserted-by":"crossref","first-page":"107287","DOI":"10.1016\/j.yebeh.2020.107287","article-title":"Nonseizure consequences of Dravet syndrome, KCNQ2-DEE, KCNB1-DEE, Lennox-Gastaut syndrome, ESES: a functional framework","volume":"111","author":"Berg","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.107958_b0015","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/epi4.12319","article-title":"Seizure burden in severe early-life epilepsy: perspectives from parents","volume":"4","author":"Berg","year":"2019","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.yebeh.2021.107958_b0020","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.yebeh.2018.11.029","article-title":"Behavior problems and health-related quality of life in Dravet syndrome","volume":"90","author":"Sinoo","year":"2019","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.107958_b0025","doi-asserted-by":"crossref","unstructured":"Health USDo, Human Services FDACfDE, Research, Health USDo, Human Services FDACfBE, Research, Health USDo, Human Services FDACfD, Radiological H. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health and quality of life outcomes 2006;4: 79-79.","DOI":"10.1186\/1477-7525-4-79"},{"key":"10.1016\/j.yebeh.2021.107958_b0030","unstructured":"U.S. Food and Drug Administration. Guidance for industry: Patient-reported outcome measures: use in medical product development to support labeling claims. Federal Register 2009;74: 65132-65133."},{"key":"10.1016\/j.yebeh.2021.107958_b0035","series-title":"Workshop on Natural History Studies of Rare Diseases","author":"FDA","year":"2012"},{"key":"10.1016\/j.yebeh.2021.107958_b0040","unstructured":"FDA. Methods to Identify What Is Important to Patients & Select, Develop or Modify Fit-for-Purpose Clinical Outcomes Assessments. In: Patient-focused drug development guidance public workshop; 2018."},{"key":"10.1016\/j.yebeh.2021.107958_b0045","unstructured":"FDA. Rare Diseases: Natural History Studies for Drug Development Guidance for Industry. In: Adminsitration FD, editor.; 2019."},{"key":"10.1016\/j.yebeh.2021.107958_b0050","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/jamaoncol.2015.0530","article-title":"Patient-reported outcomes in Cancer Drug Development and US Regulatory Review: perspectives from industry, the Food and Drug Administration, and the Patient-Reported Outcomes in Cancer Drug Research","volume":"1","author":"Basch","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.yebeh.2021.107958_b0055","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1111\/j.1524-4733.2007.00275.x","article-title":"Patient-reported outcomes to support medical product labeling claims: FDA perspective","volume":"10","author":"Patrick","year":"2007","journal-title":"Value Health"},{"key":"10.1016\/j.yebeh.2021.107958_b0060","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/MLR.0000000000000273","article-title":"Patient-focused drug development: a new direction for collaboration","volume":"53","author":"Perfetto","year":"2015","journal-title":"Med Care"},{"key":"10.1016\/j.yebeh.2021.107958_b0065","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13023-017-0718-x","article-title":"Measuring what matters to rare disease patients\u2013reflections on the work by the IRDiRC taskforce on patient-centered outcome measures","volume":"12","author":"Morel","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.yebeh.2021.107958_b0070","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yebeh.2021.107958_b0075","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","article-title":"Effect of cannabidiol on drop seizures in the Lennox-Gastaut Syndrome","volume":"378","author":"Devinsky","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yebeh.2021.107958_b0080","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/S0140-6736(19)32500-0","article-title":"Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial","volume":"394","author":"Lagae","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2021.107958_b0085","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1176\/appi.ajp.159.8.1337","article-title":"Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence","volume":"159","author":"Aman","year":"2002","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.yebeh.2021.107958_b0090","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/CHI.0b013e3181b76658","article-title":"A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder","volume":"48","author":"Marcus","year":"2009","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.yebeh.2021.107958_b0095","first-page":"485","article-title":"The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects","volume":"89","author":"Aman","year":"1985","journal-title":"Am J Ment Defic"},{"key":"10.1016\/j.yebeh.2021.107958_b0100","doi-asserted-by":"crossref","unstructured":"Karabekiroglu K, Aman MG. Validity of the aberrant behavior checklist in a clinical sample of toddlers. 2009;40: 99-110.","DOI":"10.1007\/s10578-008-0108-7"},{"key":"10.1016\/j.yebeh.2021.107958_b0105","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1192\/bjp.bp.107.044370","article-title":"Behavioural phenotype of Cornelia de Lange syndrome: case\u2013control study","volume":"193","author":"Oliver","year":"2008","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.yebeh.2021.107958_b0110","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1352\/0895-8017(1998)103<0264:PBAWDP>2.0.CO;2","article-title":"Problem behaviors associated with deletion Prader-Willi, Smith-Magenis, and cri du chat syndromes","volume":"103","author":"Clarke","year":"1998","journal-title":"Am J Mental Retardation"},{"key":"10.1016\/j.yebeh.2021.107958_b0115","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1352\/0895-8017(2000)105<0025:PBAWQA>2.0.CO;2","article-title":"Problem behaviors associated with 15q-Angelman syndrome","volume":"105","author":"Clarke","year":"2000","journal-title":"Am J Mental Retardation"},{"key":"10.1016\/j.yebeh.2021.107958_b0120","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/ajmg.a.61140","article-title":"Maladaptive behaviors in individuals with Angelman syndrome","volume":"179","author":"Sadhwani","year":"2019","journal-title":"Am J Med Genetics Part A"},{"key":"10.1016\/j.yebeh.2021.107958_b0125","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejpn.2019.12.016","article-title":"The phenotypic spectrum of SCN2A-related epilepsy","volume":"24","author":"Reynolds","year":"2020","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.yebeh.2021.107958_b0130","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s11689-018-9229-x","article-title":"Few individuals with Lennox-Gastaut syndrome have autism spectrum disorder: a comparison with Dravet syndrome","volume":"10","author":"He","year":"2018","journal-title":"J Neurodev Disord"},{"key":"10.1016\/j.yebeh.2021.107958_b0135","doi-asserted-by":"crossref","first-page":"107079","DOI":"10.1016\/j.yebeh.2020.107079","article-title":"Intellectual functioning and behavior in Dravet syndrome: a systematic review","volume":"108","author":"Jansson","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.107958_b0140","unstructured":"Bar C, Kuchenbuch M, Barcia G, Schneider A, Jennesson M, Le Guyader G et al. Developmental and epilepsy spectrum of KCNB1 encephalopathy with long-term outcome. Epilepsia 2020."},{"key":"10.1016\/j.yebeh.2021.107958_b0145","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S1525-5050(02)00537-1","article-title":"Behavioral assessment in mentally retarded and developmentally disabled patients with epilepsy","volume":"3","author":"Kerr","year":"2002","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.107958_b0150","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S1525-5050(03)00117-3","article-title":"Lamotrigine as adjunctive therapy in patients with refractory epilepsy and mental retardation","volume":"4","author":"McKee","year":"2003","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.107958_b0155","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1177\/0883073819836534","article-title":"Evaluation of the effects of clobazam on seizure control and quality of life in children with Lennox-Gastaut Syndrome: a pilot study","volume":"34","author":"Weinstock","year":"2019","journal-title":"J Child Neurol"},{"key":"10.1016\/j.yebeh.2021.107958_b0160","article-title":"Psychometric characteristics of the aberrant behavior checklist","author":"Aman","year":"1985","journal-title":"Am J Mental Def"},{"key":"10.1016\/j.yebeh.2021.107958_b0165","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s10803-013-1970-0","article-title":"Validity of the aberrant behavior checklist in children with autism spectrum disorder","volume":"44","author":"Kaat","year":"2014","journal-title":"J Autism Dev Disord"},{"key":"10.1016\/j.yebeh.2021.107958_b0170","doi-asserted-by":"crossref","unstructured":"Brinkley J, Nations L, Abramson RK, Hall A, Wright HH, Gabriels R. Factor analysis of the aberrant behavior checklist in individuals with autism spectrum disorders. 2007;37: 1949-1959.","DOI":"10.1007\/s10803-006-0327-3"},{"key":"10.1016\/j.yebeh.2021.107958_b0175","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s10803-011-1370-2","article-title":"Psychometric study of the aberrant behavior checklist in fragile X syndrome and implications for targeted treatment","volume":"42","author":"Sansone","year":"2012","journal-title":"J Autism Dev Disord"},{"key":"10.1016\/j.yebeh.2021.107958_b0180","doi-asserted-by":"crossref","first-page":"e034362","DOI":"10.1136\/bmjopen-2019-034362","article-title":"Protocol: Does cannabidiol reduce severe behavioural problems in children with intellectual disability? Study protocol for a pilot single-site phase I\/II randomised placebo controlled trial","volume":"10","author":"Efron","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.yebeh.2021.107958_b0185","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1176\/appi.ajp.162.6.1142","article-title":"Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology","volume":"162","author":"McDougle","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.yebeh.2021.107958_b0190","article-title":"Overview of four functional classification systems commonly used in cerebral palsy","volume":"4","author":"Paulson","year":"2017","journal-title":"Children (Basel)"},{"key":"10.1016\/j.yebeh.2021.107958_b0195","doi-asserted-by":"crossref","unstructured":"Morris C, Galuppi BE, Rosenbaum PL. Reliability of family report for the Gross Motor Function Classification System. Dev Med Child Neurol 2004;46: 455-460.","DOI":"10.1111\/j.1469-8749.2004.tb00505.x"},{"key":"10.1016\/j.yebeh.2021.107958_b0200","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/dmcn.13602","article-title":"Should the Gross Motor Function Classification System be used for children who do not have cerebral palsy?","volume":"60","author":"Towns","year":"2018","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.yebeh.2021.107958_b0205","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/01241398-200409000-00011","article-title":"The Functional Mobility Scale (FMS)","volume":"24","author":"Graham","year":"2004","journal-title":"J Pediatr Orthop"},{"key":"10.1016\/j.yebeh.2021.107958_b0210","doi-asserted-by":"crossref","unstructured":"Hidecker MJ, Paneth N, Rosenbaum PL, Kent RD, Lillie J, Eulenberg JB, et al. Developing and validating the Communication Function Classification System for individuals with cerebral palsy. Dev Med Child Neurol 2011;53: 704-10.","DOI":"10.1111\/j.1469-8749.2011.03996.x"},{"key":"10.1016\/j.yebeh.2021.107958_b0215","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/dmcn.12352","article-title":"Development and reliability of a system to classify the eating and drinking ability of people with cerebral palsy","volume":"56","author":"Sellers","year":"2014","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.yebeh.2021.107958_b0220","series-title":"Adaptive behavior assessment system","author":"Harrison","year":"2015"},{"key":"10.1016\/j.yebeh.2021.107958_b0225","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1469-8749.2009.03354.x","article-title":"Does parent report measure performance? A study of the construct validity of the Functional Mobility Scale","volume":"52","author":"Harvey","year":"2010","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.yebeh.2021.107958_b0230","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/dmcn.13751","article-title":"The Eating and Drinking Ability Classification System: concurrent validity and reliability in children with cerebral palsy","volume":"60","author":"Tschirren","year":"2018","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.yebeh.2021.107958_b0235","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1023\/A:1010738829569","article-title":"The Modified Checklist for Autism in Toddlers: an initial study investigating the early detection of autism and pervasive developmental disorders","volume":"31","author":"Robins","year":"2001","journal-title":"J Autism Dev Disord"},{"key":"10.1016\/j.yebeh.2021.107958_b0240","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1044\/1092-4388(2002\/097)","article-title":"Validity and reliability of the communication and symbolic behavior scales developmental profile with very young children","volume":"45","author":"Wetherby","year":"2002","journal-title":"J Speech Lang Hear Res"},{"key":"10.1016\/j.yebeh.2021.107958_b0245","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1207\/S15327906MBR3403_2","article-title":"The problem of units and the circumstance for POMP","volume":"34","author":"Cohen","year":"1999","journal-title":"Multivar Behav Res"},{"key":"10.1016\/j.yebeh.2021.107958_b0250","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1089\/cap.2019.0177","article-title":"Factor structure of the Aberrant Behavior Checklist in individuals with Fragile X syndrome: clarifications and future guidance","volume":"30","author":"Aman","year":"2020","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.yebeh.2021.107958_b0255","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/0146621605278814","article-title":"Estimating generalizability to a universe of indicators that all have one attribute in common: a comparison of estimators for omega","volume":"30","author":"Zinbarg","year":"2006","journal-title":"Appl Psychol Meas"},{"key":"10.1016\/j.yebeh.2021.107958_b0260","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1037\/1040-3590.8.4.350","article-title":"Uses and abuses of coefficient alpha","volume":"8","author":"Schmitt","year":"1996","journal-title":"Psychol Assess"},{"key":"10.1016\/j.yebeh.2021.107958_b0265","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11336-008-9102-z","article-title":"Coefficients alpha, beta, omega, and the glb: comments on Sijtsma","volume":"74","author":"Revelle","year":"2009","journal-title":"Psychometrika"},{"key":"10.1016\/j.yebeh.2021.107958_b0270","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1207\/s15327906mbr1401_4","article-title":"Hierarchical cluster analysis and the internal structure of tests","volume":"14","author":"Revelle","year":"1979","journal-title":"Multivar Behav Res"},{"key":"10.1016\/j.yebeh.2021.107958_b0275","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/1094428105283939","article-title":"Coefficient beta and hierarchical item clustering: an analytical procedure for establishing and displaying the dimensionality and homogeneity of summated scales","volume":"9","author":"Cooksey","year":"2006","journal-title":"Org Res Methods"},{"key":"10.1016\/j.yebeh.2021.107958_b0280","first-page":"1","article-title":"Implementing a class of permutation tests: the coin package","volume":"28","author":"Zeileis","year":"2008","journal-title":"J Stat Softw"},{"key":"10.1016\/j.yebeh.2021.107958_b0285","doi-asserted-by":"crossref","unstructured":"Hayes AF. Permutation test is not distribution-free: Testing H\u2080: \u03c1 = 0. In. US: American Psychological Association; 1996. p. 184-198.","DOI":"10.1037\/1082-989X.1.2.184"},{"key":"10.1016\/j.yebeh.2021.107958_b0290","doi-asserted-by":"crossref","unstructured":"DeWalt DA, Rothrock N, Yount S, Stone AA. Evaluation of item candidates: the PROMIS qualitative item review. Medical Care 2007;45: S12.","DOI":"10.1097\/01.mlr.0000254567.79743.e2"},{"key":"10.1016\/j.yebeh.2021.107958_b0295","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3109\/09638280903095890","article-title":"Parents' perspectives on occupational therapy and physical therapy goals for children with cerebral palsy","volume":"32","author":"Wiart","year":"2010","journal-title":"Disabil Rehabil"},{"key":"10.1016\/j.yebeh.2021.107958_b0300","doi-asserted-by":"crossref","unstructured":"Achenbach TM, Ruffle TM. The Child Behavior Checklist and related forms for assessing behavioral\/emotional problems and competencies. Pediatrics Rev 2000;21: 265-271.","DOI":"10.1542\/pir.21.8.265"}],"container-title":["Epilepsy &amp; Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152550502100192X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152550502100192X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:39:34Z","timestamp":1761503974000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152550502100192X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":60,"alternative-id":["S152550502100192X"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.107958","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the Aberrant Behavior Checklist for Developmental and Epileptic Encephalopathies","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.107958","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107958"}}